GitHub

AlienVault OTX API download Indicators of Compromise to a format suitable for SIEM Import

Based on original "Signature Base" code by Florian Roth / Neo23x0 @ https://github.com/Neo23x0/signature-base References https://www.bsk-consulting.de/2015/09/06 ...
AZ Central

Regenerative Orthopedics and Sports Medicine (ROSM) to Lead and Honor at AAOM OTX26

COLUMBIA, MD, UNITED STATES, March 17, 2026 /EINPresswire.com/ — Regenerative Orthopedics and Sports Medicine (ROSM), a leading provider of non-surgical orthopedic ...
IEEE

OTX AlienVault Indicator of Compromise Implementation on MISP Threat Sharing for Network Intrusion Detection System Suricata

Abstract: In the ever-evolving cyber era, cyberattack threats are increasingly diverse and elusive. Precise and complete information related to cyber attacks can be utilised to create a reliable ...
MarketWatch

Ocular Therapeutix(TM) to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Detailed SOL-1 data to be presented at the 49(th) Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated ...
Nasdaq

Ocular Therapeutics Awaits Wet AMD Trial Data, Stock Up Over 23%

(RTTNews) - Shares of Ocular Therapeutics, Inc. (OCUL), are up 23% in pre-market trading today, reflecting investor enthusiasm around the company's late-stage pipeline in retinal and glaucoma programs ...
MedCity News

BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
Reuters

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Morningstar

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...
Seeking Alpha

Bristol Myers Squibb to buy Orbital Therapeutics for $1.5B in cash

Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...
CNBC

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
FierceBiotech

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...